|
|
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| |
| |authorTag={{JH}}
| |
| |genericName=Ticagrelor
| |
| |aOrAn=a
| |
| |drugClass=P2Y12 platelet inhibitor
| |
| |indication=Acute Coronary Syndromes
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=Bleeding, headache, elevated serum creatinine, dysphnea and cough
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
| |
| |fdaLIADAdult======Acute Coronary Syndromes=====
| |
|
| |
|
| * Dosing Information
| |
| :*Initial dose: Ticagrelor 180 mg (two 90 mg tablets) PO.
| |
| ::*ACS patients who have received a loading dose of Clopidogrel may be started on Ticagrelor.
| |
| :*Maintenance dose: Ticagrelor 90 mg twice daily PO.
| |
| ::*After the initial loading dose of aspirin (usually 325 mg), use Ticagrelor with a daily maintenance dose of aspirin of 75-100 mg PO.
| |
| ::*Ticagrelor can be administered with or without food.
| |
| ::*If a patient misses a dose of Ticagrelor, should take one 90 mg tablet (their next dose) at its scheduled time.
| |
| |fdaLIADPed=dsfj
| |
| |offLabelPedGuideSupport=dsfhl
| |
| |offLabelPedNoGuideSupport=sdgljjsf
| |
| }}
| |
| {|class="infobox" style="position: fixed; top: 180px; right: 20px; margin: 0 0 0 0; border: 0; float: right; width: 15%; background: #104E8B; border-radius: 10px 10px 10px 10px;" cellpadding="0" cellspacing="0";
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #104E8B;" | [[{{PAGENAME}}|{{fontcolor|#F8F8FF|{{PAGENAME}}®}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #000000; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Black Box Warning|{{fontcolor|#FF0000|Black Box Warning}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Adult Indications and Dosage|{{fontcolor|#F8F8FF|Adult Indications and Dosage}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Pediatric Indications and Dosage|{{fontcolor|#F8F8FF|Pediatric Indications and Dosage}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Contraindications|{{fontcolor|#F8F8FF|Contraindications}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Warnings|{{fontcolor|#F8F8FF|Warnings}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Adverse Reactions|{{fontcolor|#F8F8FF|Adverse Reactions}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Drug Interactions|{{fontcolor|#F8F8FF|Drug Interactions}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Use in Specific Populations|{{fontcolor|#F8F8FF|Use in Specific Populations}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Administration and Monitoring|{{fontcolor|#F8F8FF|Administration and Monitoring}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#IV Compatibility|{{fontcolor|#F8F8FF|IV Compatibility}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Overdosage|{{fontcolor|#F8F8FF|Overdosage}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Pharmacology|{{fontcolor|#F8F8FF|Pharmacology}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Clinical Studies|{{fontcolor|#F8F8FF|Clinical Studies}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#How Supplied|{{fontcolor|#F8F8FF|How Supplied}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Images|{{fontcolor|#F8F8FF|Images}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Patient Information|{{fontcolor|#F8F8FF|Patient information}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Precautions with Alcohol|{{fontcolor|#F8F8FF|Precautions with Alcohol}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Brand Names|{{fontcolor|#F8F8FF|Brand Names}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Look-Alike Drug Names|{{fontcolor|#F8F8FF|Look-Alike Drug Names}}]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792.htm {{fontcolor|#F8F8FF|Drug Shortage Status}}]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [http://www.goodrx.com/{{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}/price {{fontcolor|#F8F8FF|Price}}]
| |
| |-
| |
| |}
| |